Program Co-leader: Li Mao, M.D.
Program Co-leader: Maria R. Baer, M.D.
See the complete list of Experimental Therapeutics investigators.
The Experimental Therapeutics Program (ET) consists of members from
the School of Medicine (representing several departments) and the School of
Pharmacy. Program members are supported by many individual peer-reviewed grants.
The unifying theme of this Program is to build translational clinical trials
based on innovative and novel laboratory research projects.
The Program's scientific goals are:
- Identification of novel genes and proteins that are important targets in cancer treatment
- Design and development of new drugs aimed at the targets identified
- Design, conduct, and analyze innovative clinical trials that focus on the molecular targets identified, with the ultimate goal
being the development of improved diagnostic or therapeutic agents for cancer
To accomplish these goals, the ET Program is composed
of interacting groups of investigators working in the following thematic areas:
- Cancer drug resistance
- Cell proliferation, signaling, growth factors, and apoptosis
- Computer-Assisted Drug Design and Screening (CADDS)
- Clinical trials that specifically test the efficacy of agents aimed at novel targets
ET program activities are greatly enhanced
by extensive interactions with other cancer center programs. Program members
are frequent users of Cancer Center Shared Services. The Cancer Center also
supports monthly Program meetings and yearly Program scientific retreats. The
increasing numbers of cancer-directed translational and clinical studies developed by program members is a manifestation of the success of this program.
This page was last updated: June 11, 2015